NEW YORK, NY / ACCESSWIRE / February 28, 2018 / U.S. markets dropped for the first time in four sessions on Tuesday as comments made by new Federal Reserve Chairman Jerome Powell hinted interest rates could rise more quickly this year. The Dow Jones Industrial declined 1.16 percent to close at 25,410.03, while the S&P 500 Index dropped 1.27 percent to close at 2,744.28. The Nasdaq Composite Index fell 1.23 percent to close at 7,330.35. The yield on the benchmark 10-year Treasury note jumped 5 basis points to 2.915 percent.
“We’ve seen continuing strength in the labor market. We’ve seen some data that will, in my case, add some confidence to my view that inflation is moving up to target. We’ve also seen continued strength around the globe, and we’ve seen fiscal policy become more stimulative,” Powell said in testimony, according to MarketWatch.
RDI Initiates Coverage on:
Clovis Oncology, Inc.
https://rdinvesting.com/news/?ticker=CLVS
Exact Sciences Corporation
https://rdinvesting.com/news/?ticker=EXAS
Clovis Oncology’s stock jumped 6.56% Tuesday, to close the day at $59.15. The stock recorded a trading volume of 3,057,743 shares, which was above its three months average volume of 1,301,032 shares. In the last year, Clovis Oncology’s shares have traded in a range of 45.42 – 99.45. The share price has gained 30.23% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $57.40 is below its 200-day moving average of $67.62. Shares of Clovis Oncology have fallen roughly 4.21 percent in the past month and are down 13.01 percent year-to-date.
Access RDI’s Clovis Oncology, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CLVS
On Tuesday, shares of Exact Sciences recorded a trading volume of 4,379,024 shares, which was above the three months average volume of 2,650,740 shares. The stock ended the day 4.25% higher at 44.37. The share price has gained 122.85% from its 52 week low with a 52 week trading range of 19.91 – 63.60. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $48.90 is below its 200-day moving average of $49.39. Shares of Exact Sciences have fallen roughly 11.38 percent in the past month and are down 15.55 percent year-to-date.
Access RDI’s Exact Sciences Corporation Research Report at:
https://rdinvesting.com/news/?ticker=EXAS
Our Actionable Research on Clovis Oncology, Inc. (NASDAQ:CLVS) and Exact Sciences Corporation (NASDAQ:EXAS) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
ReleaseID: 491181
